Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate (Q28360226)

1

0 references

C J Allegra

2

0 references

J C Swan

3

0 references

J C Drake

4

0 references

J E Parrillo

5

0 references

B A Chabner

6

0 references

H Masur

Antimicrobial Agents and Chemotherapy

7

0 references

language of work or name

English

0 references

publication date

April 1988

0 references

published in

0 references

volume

32

0 references

issue

4

0 references

page(s)

430-3

0 references

cites work

Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=172195

Activity of lipid-soluble inhibitors of dihydrofolate reductase against Pneumocystis carinii in culture and in a rat model of infection

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=172195

TECHNIQUES FOR STUDY OF RESISTANCE TO FOLIC ACID ANTAGONISTS

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=172195

Cerebral toxoplasmosis complicating the acquired immune deficiency syndrome: clinical and neuropathological findings in 27 patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=172195

Assessment of therapy for toxoplasma encephalitis. The TE Study Group

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=172195

Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=172195

Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=172195

Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=172195

In vivo activity of piritrexim [corrected] against Toxoplasma gondii

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=172195

Potent effect of trimetrexate, a lipid-soluble antifolate, on Toxoplasma gondii

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=172195

Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=172195

Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features

2 June 2018

1 reference

12 December 2020

Pneumocystis carinii Pneumonia: A Comparison Between Patients with the Acquired Immunodeficiency Syndrome and Patients with Other Immunodeficiencies

1 reference

12 December 2020

Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial

1 reference

12 December 2020

Phase I studies with trimetrexate: clinical pharmacology, analytical methodology, and pharmacokinetics

1 reference

12 December 2020

Toxoplasma encephalitis in patients with acquired immune deficiency syndrome: diagnosis and response to therapy

1 reference

12 December 2020